Indivior Pharmaceuticals, Inc.
Financials
Valuation Metrics
Indivior Pharmaceuticals, Inc.'s Market Cap is $4.29B. At end of 2025 it was $4.49B. Ranked #1473 of 3,118 in US market (top 47%), #507 of 1,474 on NASDAQ (top 34%), #83 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 31%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.29B | US#1,473/3,118 Sec#83/265 |
| Revenue | $1.37B | US#1,696/3,118 Sec#44/265 |
| Net Income | $450M | US#1,009/3,118 Sec#33/265 |
| Total Assets | $1.33B | US#2,370/3,118 Sec#81/265 |
| Net Assets | $-60M | US#2,980/3,118 Sec#257/265 |
| Employees | 827 | US#2,062/3,118 Sec#61/265 |
| Value | ||
| P/E | 9.53x | US#514/3,118 Sec#16/265 |
| PEG | 0.06x | US#157/3,118 Sec#8/265 |
| P/S | 3.12x | US#1,780/3,118 Sec#54/265 |
| EV/EBITDA | 7.89x | US#859/3,118 Sec#25/265 |
| FCF Yield | 0.72% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | 33.78% | US#42/3,118 Sec#9/265 |
| Op. Margin | 43.67% | US#303/3,118 Sec#17/265 |
| Revenue Growth | 16.34% | US#993/3,118 Sec#84/265 |
| Earnings Growth | 171.08% | US#170/3,118 Sec#10/265 |
| Financial Health | ||
| Total Debt | $501M | US#1,858/3,118 Sec#63/265 |
| FCF | $31M | US#2,650/3,118 Sec#154/265 |
| Cash | $305M | US#1,651/3,118 Sec#100/265 |
| Current Ratio | 0.61x | US#2,455/3,118 Sec#261/265 |
| Net Debt/EBITDA | 0.35x | US#839/3,118 Sec#42/265 |
| Performance | ||
| 1Y Return | 23.49% | US#1,096/3,118 Sec#103/265 |
| 1M Return | 1.57% | US#1,919/3,118 Sec#126/265 |
| From 52W High | -15.28% | US#1,340/3,118 Sec#70/265 |
| 1Y MDD | -22.42% | US#787/3,118 Sec#30/265 |
| Trading | ||
| Volume | 2,428,579 shares | US#676/3,118 Sec#55/265 |
| Trading Value | $88M | US#858/3,118 Sec#45/265 |
| Per Share | ||
| EPS | $3.81 | US#1,047/3,118 Sec#30/265 |
| BPS | $-0.51 | US—/3,118 Sec—/265 |
Company Info
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.